Literature DB >> 21097776

Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.

Porcia T Bradford1, Alisa M Goldstein, Deborah Tamura, Sikandar G Khan, Takahiro Ueda, Jennifer Boyle, Kyu-Seon Oh, Kyoko Imoto, Hiroki Inui, Shin-Ichi Moriwaki, Steffen Emmert, Kristen M Pike, Arati Raziuddin, Teri M Plona, John J DiGiovanna, Margaret A Tucker, Kenneth H Kraemer.   

Abstract

BACKGROUND: The frequency of cancer, neurologic degeneration and mortality in xeroderma pigmentosum (XP) patients with defective DNA repair was determined in a four decade natural history study.
METHODS: All 106 XP patients admitted to the National Institutes of Health from 1971 to 2009 were evaluated from clinical records and follow-up.
RESULTS: In the 65 per cent (n=69) of patients with skin cancer, non-melanoma skin cancer (NMSC) was increased 10,000-fold and melanoma was increased 2000-fold in patients under age 20. The 9 year median age at diagnosis of first non-melanoma skin cancer (NMSC) (n=64) was significantly younger than the 22 year median age at diagnosis of first melanoma (n=38)-a relative age reversal from the general population suggesting different mechanisms of carcinogenesis between NMSC and melanoma. XP patients with pronounced burning on minimal sun exposure (n=65) were less likely to develop skin cancer than those who did not. This may be related to the extreme sun protection they receive from an earlier age, decreasing their total ultraviolet exposure. Progressive neurologic degeneration was present in 24% (n=25) with 16/25 in complementation group XP-D. The most common causes of death were skin cancer (34%, n=10), neurologic degeneration (31%, n=9), and internal cancer (17%, n=5). The median age at death (29 years) in XP patients with neurodegeneration was significantly younger than those XP patients without neurodegeneration (37 years) (p=0.02).
CONCLUSION: This 39 year follow-up study of XP patients indicates a major role of DNA repair genes in the aetiology of skin cancer and neurologic degeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097776      PMCID: PMC3235003          DOI: 10.1136/jmg.2010.083022

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  70 in total

1.  Reduced DNA repair in cultured melanocytes and nevus cells from a patient with xeroderma pigmentosum.

Authors:  K H Kraemer; M Herlyn; S H Yuspa; W H Clark; G K Townsend; G R Neises; V J Hearing
Journal:  Arch Dermatol       Date:  1989-02

2.  Xeroderma pigmentosum. Defective DNA repair causes skin cancer and neurodegeneration.

Authors:  J H Robbins
Journal:  JAMA       Date:  1988-07-15       Impact factor: 56.272

3.  Neurological disease in xeroderma pigmentosum. Documentation of a late onset type of the juvenile onset form.

Authors:  J H Robbins; R A Brumback; M Mendiones; S F Barrett; J R Carl; S Cho; M B Denckla; M B Ganges; L H Gerber; R A Guthrie
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

4.  DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum.

Authors:  K H Kraemer; M M Lee; J Scotto
Journal:  Carcinogenesis       Date:  1984-04       Impact factor: 4.944

5.  Clinically asymptomatic xeroderma pigmentosum neurological disease in an adult: evidence for a neurodegeneration in later life caused by defective DNA repair.

Authors:  J H Robbins; R A Brumback; A N Moshell
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

6.  Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases.

Authors:  K H Kraemer; M M Lee; J Scotto
Journal:  Arch Dermatol       Date:  1987-02

7.  Evidence that lack of deoxyribonucleic acid repair causes death of neurons in xeroderma pigmentosum.

Authors:  J H Robbins; R J Polinsky; A N Moshell
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

8.  Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.

Authors:  K H Kraemer; J J DiGiovanna; A N Moshell; R E Tarone; G L Peck
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

9.  Xeroderma pigmentosum exhibiting neurological disorders and systemic lupus erythematosus.

Authors:  J Hananian; J E Cleaver
Journal:  Clin Genet       Date:  1980-01       Impact factor: 4.438

10.  The emerging epidemic of melanoma and squamous cell skin cancer.

Authors:  A G Glass; R N Hoover
Journal:  JAMA       Date:  1989-10-20       Impact factor: 56.272

View more
  150 in total

1.  Use of Big Data to Estimate Prevalence of Defective DNA Repair Variants in the US Population.

Authors:  Jennifer Pugh; Sikandar G Khan; Deborah Tamura; Alisa M Goldstein; Maria Teresa Landi; John J DiGiovanna; Kenneth H Kraemer
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Regulation and disregulation of mammalian nucleotide excision repair: a pathway to nongermline breast carcinogenesis.

Authors:  Jean J Latimer; Vongai J Majekwana; Yashira R Pabón-Padín; Manasi R Pimpley; Stephen G Grant
Journal:  Photochem Photobiol       Date:  2014-12-19       Impact factor: 3.421

3.  Ocular manifestations of trichothiodystrophy.

Authors:  Brian P Brooks; Amy H Thompson; Janine A Clayton; Chi-Chao Chan; Deborah Tamura; Wadih M Zein; Delphine Blain; Casey Hadsall; John Rowan; Kristen E Bowles; Sikandar G Khan; Takahiro Ueda; Jennifer Boyle; Kyu-Seon Oh; John J DiGiovanna; Kenneth H Kraemer
Journal:  Ophthalmology       Date:  2011-09-28       Impact factor: 12.079

Review 4.  [Light protection for xeroderma pigmentosum].

Authors:  M Ettinger; M Berneburg
Journal:  Hautarzt       Date:  2017-05       Impact factor: 0.751

5.  High prevalence of vitamin D deficiency in patients with xeroderma pigmetosum-A under strict sun protection.

Authors:  A Kuwabara; N Tsugawa; K Tanaka; Y Uejima; J Ogawa; N Otao; N Yamada; T Masaki; C Nishigori; S Moriwaki; T Okano
Journal:  Eur J Clin Nutr       Date:  2015-02-11       Impact factor: 4.016

Review 6.  Clinical utility gene card for: Xeroderma pigmentosum.

Authors:  Steffen Schubert; Janin Lehmann; Limor Kalfon; Hanoch Slor; Tzipora C Falik-Zaccai; Steffen Emmert
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

Review 7.  Clinical applications of melanoma genetics.

Authors:  Michele Gabree; Devanshi Patel; Linda Rodgers
Journal:  Curr Treat Options Oncol       Date:  2014-06

8.  Analysis of DNA binding by human factor xeroderma pigmentosum complementation group A (XPA) provides insight into its interactions with nucleotide excision repair substrates.

Authors:  Norie Sugitani; Markus W Voehler; Michelle S Roh; Agnieszka M Topolska-Woś; Walter J Chazin
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

9.  Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons.

Authors:  Christiane Kuschal; John J DiGiovanna; Sikandar G Khan; Richard A Gatti; Kenneth H Kraemer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 10.  Discriminating Nevi from Melanomas: Clues and Pitfalls.

Authors:  Cristina Carrera; Ashfaq A Marghoob
Journal:  Dermatol Clin       Date:  2016-10       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.